According to the publicity department of the Taizhou Municipal Party Committee of Zhejiang Province, on February 15, “Faviravir” (formerly known as “Fapiravir”) developed by Zhejiang Haizheng Pharmaceutical Co. This is the first drug with potential therapeutic effect on C.N.C.P. approved for marketing in China during the epidemic, which will play an important role in the prevention and treatment of the epidemic. According to the news released by the Ministry of Science and Technology on February 15, Fapiravir is one of the three western drugs currently in clinical trials for the treatment of neocoronaryngitis (the other two are: chloroquine phosphate and raltegravir), and has initially demonstrated a more pronounced efficacy and lower adverse effects for the treatment of neocoronaryngitis. It is reported that the drug has been officially put into production on February 16th in Hai Zheng Pharmaceutical. After the new crown pneumonia outbreak, Zhejiang Provincial Drug Administration and Taizhou Municipal Market Supervision Bureau two-level linkage, take the initiative as, intervene in advance, and fully assist the city’s pharmaceutical enterprises in the research and development of the production of drugs for the treatment of the new crown pneumonia, only 10 days to complete all the registration and approval process. First, research in advance to develop a service list. The first time to identify the city’s antiviral drug production and research and development situation to see, in a timely manner to grasp the needs of enterprises, clear focus on business and service list, the list involves the project R & D and production of technical guidance, raw materials and materials procurement to ensure that the three major aspects of the epidemic protection and so on, a total of 19 issues. Second, the implementation of the “three specialties” to help crack the problem. Municipal Bureau in the province took the lead in the introduction of anti-epidemic drug production enterprises stationed mentor system, take the initiative to docking enterprises, to understand the degree of progress in the registration of Fabipravir, and actively docking with the higher authorities to help enterprises enter the rapid review and approval channel, February 5, it was successfully accepted. The backbone GMP inspectors were selected to act as inspectors and observers to assist in the registration review, and the approval was granted on February 15th. Third, the whole process of tracking and guiding the compliant production. The implementation of special guidance + commissioner stationed + expert help “three special” services. Municipal Bureau of leadership team composed of expert groups, to help enterprises to do a good job in pre-production pharmaceutical compliance preparations, to help enterprises to complete the production line in advance of the inspection, so that the document number was approved immediately can be organized for production, the steering group of commissioners to implement the full tracking guidance to ensure that the quality and safety of listed medicines to help fight the new Crown pneumonia outbreak. Source: New Beijing News